Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas

(1)

Table 1: List of antibodies used for immunohistochemistry on cutaneous biopsies

Antigen Clone Specificity Source

CD1a 010 Langerhans cells Dako

PS100 polyclonal Langerhans cells Dako

CD3 polyclonal T-cells Dako

CD4 1F6 T-helper/inducer cells Novocastra

CD8 C8/144 T-suppressor/cytotoxic cells Dako

CD20 L26 B-cells Dako

CD56 123C3 NK cells Zymed

CD68 PGM1 monocytes-macrophages Dako

GFAP 6F2 astrocytes Dako

(2)

Table 2: Patient characteristics. GB, glioblastoma; OIII, anaplastic oligodendroglioma;

OAIII, anaplastic oligoastrocytoma; E, surgical exerese; RXT, radiotherapy; T, temodal;

PCV, procarbazine-CCNU-vincristine; TO, topotecan; VP-16, oral ectoposide; BCNU, carmustine; ST, sub-total; GR, gross-total; PD, progressive disease; S, stable; NA, non applicable; ^a at the time of the vaccination;^b 8 weeks after the final vaccination; ^c from the second surgery date.

N° Age Tumor pathology

Prevaccination Treatment

Surgery KI^a Tumor size (mm)^a

Protocol number

Vaccin (number)

Response^b Survival (weeks)^c

1 40 GB E, RXT, T ST 30 9060 1 Yes (2) PD 9.5

2 33 OIII E, PCV, RXT ST 40 2831 831

1 Yes (3) PD 25

3 38 GB E, RXT ST 50 NA 1 No NA 6.5

4 65 GB E, RXT GR 50 3522 1 Yes (2) S 61.8

5 61 GB E, TO, RXT GR 100 4810 1 Yes (2) S 42

6 48 GB E, RXT ST 50 NA 1 No NA 17

7 45 OIII E, PCV, RXT GR 50 NA 1 No NA 28

8 57 GB E, RXT, T, VP-16

ST 90 0 2 Yes (4) S 88

9 62 OAIII E, RXT, T, BCNU

ST 60 74 2 No NA 17